This site contains promotional information that is intended for UK healthcare professionals who have an interest in uveal melanoma. Adverse event reporting details can be found in the footer.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ . Adverse events should also be reported to Immunocore Ltd. by calling 00 800 74451111 (Freephone) or by email: medinfo.eu@immunocore.com.
Click here to view the Summary of Product Characteristics.
Click here to contact an IMMUNOCORE Representative
Job code: PM-UK-KIM-2600039 DOP June 2026
KIMMTRAK is the first treatment specifically authorised for human leukocyte antigen (HLA)-A*02:01-positive adult patients with mUM, now with a demonstrated 5-year follow-up OS benefit vs investigator's choice (IC) of immune checkpoint inhibitors or chemotherapya.1,2
aImmune checkpoint inhibitors – pembrolizumab or ipilimumab; chemotherapy – dacarbazine.
KIMMTRAK▼ (tebentafusp) is indicated as monotherapy for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic UM.2
KIMMTRAK is recommended by:
ESMO-EURACAN as first-line standard of care for HLA-A*02:01-positive patients with mUM unless liver-directed debulking treatment is required first (level I, grade A).3
NICE: “Tebentafusp is recommended, within its marketing authorisation, for treating HLA A*02:01-positive unresectable or metastatic uveal melanoma in adults"4
KIMMTRAK doubled the OS rate vs IC at 5 years (5-year OS of 16% vs 8%),1 with a manageable adverse event (AE) profile and an AE-related discontinuation rate of 2% vs 5% with IC.5,6
Explore KIMMTRAK’s key features, its pivotal efficacy and safety data, dosing and administration information, and resources for further information and support
About KIMMTRAK
Learn about the unmet need in mUM, and KIMMTRAK as first-line treatment in this setting and its mechanism of action
Efficacy
Find out about the KIMMTRAK pivotal Phase 3 trial design and explore the key efficacy data, including for up to 5 years of follow-up
Resources and support
Discover helpful resources for further support and information about KIMMTRAK.
AE, adverse event; ESMO-EURACAN, European Society for Medical Oncology - European Reference Network for Rare Adult Solid Cancers; HLA, human leukocyte antigen; IC, investigator’s choice of pembrolizumab, ipilimumab or dacarbazine; chemotherapy; mUM, metastatic uveal melanoma; OS, overall survival.
© NICE 2025 Tebentafusp for treating advanced uveal melanoma. Available from https://www.nice.org.uk/guidance/ta1027. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to Immunocore Ltd. by calling UK local number +44 203 996 7074 or Toll free number +00 800-74451111. Alternatively, email: medinfo.eu@immunocore.com.
Click here to view the Summary of Product Characteristics.
Click here to contact an IMMUNOCORE Representative
Job code: PM-UK-KIM-2600039 DOP June 2026
You are now leaving an Immunocore website. Immunocore is not responsible for the content, except where it has supplied or reviewed the content, availability, or terms of use of third-party sites, and accepts no liability for any loss or damage resulting from their use. Please review the legal and privacy policies of any site you visit.
